Treatment of dyslipidemic patients with high or very high risk for the prevention of cardiovascular events in Europe -Multinational Observational Study.
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: DAIICHI SANKYO EUROPE GMBH
- Execution start: 08/10/2020
- End of execution: 30/12/2022
- PI: JUAN DIEGO MEDIAVILLA GARCIA